InflaRx
Developing new therapeutics in the terminal complement space.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $30.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 163 % | (54 %) | 185 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (63756 %) | (29691 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (67632 %) | (27785 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | 65027 % | 21331 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
InflaRx N.V., headquartered in Jena, Germany, is a clinical-stage biopharmaceutical company specializing in the development of monoclonal antibodies that target activation products of the complement system. The company focuses on addressing acute and chronic inflammation through innovative therapeutic solutions. InflaRx's primary clients include healthcare providers and research institutions that require advanced treatments for life-threatening inflammatory diseases. Operating in the biopharmaceutical market, InflaRx employs a business model centered on research and development, clinical trials, and eventual commercialization of its drug candidates. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. InflaRx's lead drug candidate, IFX-1, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical phase II development. Another promising candidate, IFX-2, is in preclinical development and aims to offer highly potent anti-complement C5a antibody solutions.
Keywords: monoclonal antibodies, complement system, inflammatory diseases, biopharmaceutical, clinical trials, IFX-1, IFX-2, C5a, therapeutic solutions, healthcare providers.